MD Anderson Cancer Center is a globally recognized cancer research organization. With emphasis on cancer patient care, research, education, and prevention, the center is devoted to the goal of eliminating cancer worldwide. To support this cause, WAT Med will…
VANCOUVER, British Columbia, Oct. 31, 2018 /PRNewswire/ — WAT Medical would go back 2018 Medica Show to exhibit innovative wearable technologies EmeTerm, an anti-vomiting wrist band, and HeadaTerm, an anti-migraine head patch. WAT Medical is a company located in Canada…
VANCOUVER, British Columbia, Oct. 5, 2018 /PRNewswire/ –Terveystekniikka Oy, a strategic partner of WAT Medical Enterprise Ltd. (WAT Med), will participate in “I love me 2018”, the biggest health expo of Finland held from October 19-21, 2018. HeadaTerm and EmeTerm, signature medical devices developed by WAT Med, will be promoted during…
WAT Medical’s innovative technology to treat all primary headaches, HeadaTerm, received its FDA clearance in September, 2018. This product, already approved by CE, HC, and now FDA, has been distributed in over 20 countries around the world. It has now…
On August 20, 2018, Benny, CEO of B. Medical, visited WAT Med. Both parties held an in-depth discussion of the cooperation details concerning the strategic layout of Israeli market and the brand building. Benny and WAT Med knew each other…
September 25 @ 8:00 AM – 9:30 AM You are invited to attend LifeSciences BC’s 2018 Annual General Meeting. The meeting will review the past fiscal year and preview plans for the current fiscal year. A continental breakfast will be…
For more information, please visit: www.amazon.com
Shortly after WAT Medical’s leading product to treat nausea-induced vomiting, EmeTerm, received its FDA clearance earlier in April, it has now also received official clearance from Health Canada. Health Canada ensures all of its certified medical products are of the…